4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Xilio Therapeutics, Inc. (XLO) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 76 employees. Its market capitalization is roughly $60 million. In the fiscal year ended 2025-12-31, XLO reported $44M in revenue and ($35M) in net income.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
Interactive charts & full statements → Open the XLO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $44M | $6M | $0M | $0M |
| Operating Income (EBIT) | ($42M) | ($60M) | ($79M) | ($89M) |
| Net Income | ($35M) | ($58M) | ($76M) | ($88M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $13M | $14M | $19M | $8M | $3M | — |
| Operating Income (EBIT) | ($14M) | ($12M) | ($2M) | ($14M) | ($14M) | — |
| Net Income | ($10M) | $10M | ($16M) | ($16M) | ($13M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $155M | $71M | $61M | $139M | — |
| Total Liabilities | $119M | $54M | $24M | $34M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XLO viewer.
About TickerBase · Data methodology & sources